Kornimate/medical-research-clean huggingface dataset:
culturally tailored behavioral diabetes care intervention for korean americans

Conditions: Diabetes

Summary: the purpose of this study is to assess the feasibility and efficacy of a culturally-tailored, comprehensive behavioral intervention program specially designed for linguistically challenged ethnic minority immigrant populations (korean americans) with type 2 dm.

korean american immigrants (kai), one of the most underserved and understudied minority populations in the u.s., suffer from diabetes, which goes under-diagnosed, inadequately treated and has a potential to result in costly and tragic consequences. language barriers, the lack of self-confidence, and diminished social support that accompany the acculturation process prevent kai from improving their health-seeking behaviors. our previous research has indicated that overwhelming numbers of kai suffer not only from uncontrolled hyperglycemia but also from a loss of self-confidence and social isolation because of language and cultural barriers. they are in urgent need of an intervention to assist them in their efforts to achieve better glycemic control and restore their self-confidence in diabetes and health management so that they are able to adjust successfully in this new environment. therefore, the purpose of this study is to assess the feasibility and efficacy of a culturally-tailored, comprehensive behavioral intervention program specially designed for linguistically challenged kais with type 2 dm. this pilot project will test the hypothesis: compared to kai in the control group, kai with type 2 dm who receive a comprehensive dm management intervention through structured psycho-behavioral education, home glucose monitoring with a telephone transmission system, and interaction with a bilingual nurse case manager will show: (1) a greater level of glucose control; and (2) a greater level of self-help skills including knowledge related to glucose control, problem-solving skills, heightened confidence and mood/affect, adherence to treatment recommendations, and quality of life. an additional outcome will be to measure and obtain an ideal bp as the proposed intervention focuses on management of multiple risk factors with which many ka dm patients often struggle.

Eligibility criteria:
inclusion criteria: * self-identified as a first generation korean american * age 30 years or older * resides in washington-baltimore area * expresses willingness to participate in all aspects of the study over its full course * written consent to participate in the screening/eligibility visit * self-identified with dm and hba1c \>= 8% within 6 months of screening * written consent to participate in the clinical trial: agreeing to participate in study data collection procedures, receiving dm self -help education, using hgmt, and permitting contact with their own medical care provider. exclusion criteria: * unable to give informed consent * physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases) * hematological condition that would affect a1c assay, e.g., hemolytic anemia, sickle cell anemia.
paf for the treatment of osteoarthritis

Conditions: Osteo Arthritis Knee

Summary: this is a phase i/ii randomized double-blinded standard of care (corticosteroid) vs. sterile amniotic fluid for osteoarthritis

this study will look at blinded standard of care (soc) steroid injection vs. amniotic fluid injection (paf) to treat and reduce osteoarthritis (oa) inflammation and pain. the main objectives of this study are to establish the safety and tolerability of allogeneic intra-articular paf injections. secondary objectives include pain levels and functional outcome scoring in patients over a 12 month time frame.

Eligibility criteria:
inclusion criteria: * patients who are between the ages of 18-70 years * a confirmed diagnosis of knee osteoarthritis based on clinical and radiographic findings consistent with kellgren-lawrence stage 2-3 disease * patients who have failed conservative treatment (e.g. steroid, activity modification, therapy, etc.) within 3 months * unilateral or bilateral chronic knee joint pain \>4 months * patients who are able to ambulate (i.e. not wheelchair bound) * patient reported a typical pain of at least 4 out of 10 during the past week using vas numeric pain scale (0-10) * patients who are of childbearing potential must agree to use adequate contraception for 90 days after study drug injection exclusion criteria: * subjects who have had a previous injection (i.e. steroid, platelet rich plasma, or other) within the last 3 months * a focal chondral defect, defined by x-ray evaluation * bmi \>40 as defined by nih clinical guidelines body mass index * concurrent participation in another investigational trial involving systemic administration of agents (within the previous 30 days) or plans to participate in any other allogeneic stem cell therapy trial during the 12 month follow-up period * clinical suspicion of infection at injection site * any surgeries within 4 weeks, other than diagnostic surgery * insulin or self-reported non-insulin dependent diabetic evident of hga1c ≥8% among known diabetics * unable to consent to an english language consent form * frank mechanical issues (i.e. locking of the knee) * workman's compensation cases * rheumatoid arthritis * patients with a known allergy to local anesthetics or components of the study drug (paf or steroid injection) * patients with vascular claudication or neurologic disorders affecting the index lower limb * patients with inflammatory arthropathies or connective tissue disorders; or * patients with known alcohol or drug abuse or dependence, recreational use of illicit drug or prescription medications, or have used medical marijuana within 7 days of study enrollment * patients with history of active cancer/malignancy within 2 years of screening, apart from adequately treated basal cell or squamous cell carcinoma of the skin not associated with the target knee * women who are nursing or pregnant * patients of childbearing potential who are unwilling to use adequate contraception for 90 days after study drug injection

Keywords: amniotic fluid osteo arthritis
extension study on safety of long-term growth hormone replacement in adult patients with growth hormone deficiency

Conditions: Adult Growth Hormone Deficiency

Summary: to evaluate long-term safety of growth hormone replacement in adult patients with growth hormone deficiency


Eligibility criteria:
inclusion criteria: * having completed the preceding long-term study of growth hormone replacement in adult patients diagnosed with growth hormone deficiency. * other pituitary hormone deficiencies being replaced if appropriate exclusion criteria: * with severe impairments of cardiac, pulmonary, renal or hepatic functions * with severe psychological disorders * with malignant cancer * with hypertension uncontrolled * with diabetes mellitus
efficacy and safety in poorly controlled type 2 diabetics

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to gain safety and efficacy information in patients with type 2 diabetes, who have not previously taken any oral antidiabetic medications, and who have an hba1c value of greater than or equal to 10%, despite diet and exercise.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * drug-naive. * laboratory test result for hba1c of greater than or equal to 10%. * written informed consent. exclusion criteria: * prior use of antidiabetic medications within 3 months of screening. * fluid retention (edema). * significant liver disease. * low red blood cells (anemia). * severe or unstable angina (chest pain). * congestive heart failure. * severe high blood pressure. * alcohol or drug abuse. * other inclusion or exclusion criteria to be determined by the physician and study sponsor.

Keywords: type 2 diabetes drug-naive
clinical evolution and becoming of adult patients infected with covid-19 hospitalized at strasbourg university hospitals

Conditions: Covid-19

Summary: a sars-cov-2 infection emerged in china in december 2019, the severity of which is linked to acute respiratory distress syndrome1. the rate of emergency visits in bas-rhin for suspected covid-19 increased, compared to the french average, at the end of the 10th week of 2020. compared to the onset of symptoms, chinese studies estimate the onset of dyspnea on the 7th day3 and admission to the emergency room between the 5th and the 9th day4. but this duration varies according to the epidemic period5, the geographical location6 and a later emergency admission is associated with an increase in mortality in the chinese population7. the need for oxygen, which is not noted in chinese studies8, is a reflection of the onset of respiratory worsening and a major factor in hospitalization. there is no study on the changing profile of the french population to date its onset.


Eligibility criteria:
inclusion criteria: * male or female aged 18 or over * admitted to the nhc emergency room and hospitalized at the strasbourg university hospitals (hus) between 06/03/2020 and 05/04/2020. * with sars-cov-2 rt-pcr on a positive nasopharyngeal sample taken at the su. exclusion criteria: * refusal to participate in the study * return home from the su * transfer to another establishment * patient under the protection of justice * patient under guardianship, curatorship

Keywords: covid-19 covid-19 pandemic sars-cov-2 emergency department
non-invasive brain stimulation for treating symptomatic convergence insufficiency

Conditions: Convergence Insufficiency

Summary: the goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. the main questions it aims to answer are: 1. can non-invasive brain stimulation shorten the treatment time of office-based vergence/accommodative therapy for convergence insufficiency? 2. is non-invasive brain stimulation alone just as effective as office-based vergence/accommodative therapy in treating convergence insufficiency? the investigators hypothesize that non-invasive brain stimulation will shorten the treatment time from 12 weeks to 8 weeks of office-based vergence/accommodative therapy and that non-invasive brain stimulation alone would be equally effective as office-based vergence/accommodative therapy in improving symptomatic convergence insufficiency. participants will be randomized into one of three treatment groups: 1. non-invasive brain stimulation with office-based vergence/accommodative therapy. 2. sham stimulation with office-based vergence/accommodative therapy. 3. non-invasive brain stimulation only. researchers will compare baseline measurements of near point of convergence (npc) and positive fusional vergence (pfv) to post-treatment measurements for each group.


Eligibility criteria:
inclusion criteria: * best-corrected visual acuity of \> 20/25 in each eye at distance and near * exophoria at near at least 4∆ greater than at far * receded near point of convergence of \> 6 cm break * insufficient positive fusional vergence at near (\< 15∆ base-out blur or break) * ciss score of 16 and greater for children or 21 and greater for adults * have had a dilated fundus examination within the last 12 months * informed consent and willingness to participate in the study and be randomized exclusion criteria: * previously treated for convergence insufficiency with home- or office-based vergence/accommodative therapy * amblyopia (\> 2-line difference in best-corrected visual acuity between the two eyes) * constant strabismus * history of strabismus surgery * convergence insufficiency secondary to acquired brain injury or neurological disorder * manifest or latent nystagmus * systemic disease known to affect accommodation, vergence, and ocular motility including multiple sclerosis, graves disease, myasthenia gravis, parkinson's disease, cerebral palsy, and diabetes * developmental disability, attention deficit hyperactivity disorder (adhd), learning disability or cognitive dysfunction that would interfere with treatment * taking medications that can affect normal neurological function including antipsychotics, antiepileptics, and opioids * presence of metal or electronic implants in or on the body, including pacemakers

Keywords: convergence insufficiency non-invasive brain stimulation office-based vergence/accommodative therapy frontal eye fields transcranial direct current stimulation
high flow nasal oxygen therapy in perioperative period of the adult with hypercapnic and hypoxemic respiratory faliure

Conditions: Acute Respiratory Failure With Hypercapnia

Summary: the purpose of this study is to determine the impact of hign-flow nasal therapy on the adult with hypercapnia and hpoxemia respiratory faliure in comparison with standard oxygen therapy ang noninvasive ventilation.

humidified high flow nasal oxygen therapy decreases dilution of the inhaled oxygen and, by matching patient's peak flow, allows accurate delivery of the set fio2 throughout the whole inspiratory phase.the purpose of this study is to determine the impact of hign-flow nasal therapy on adult hypercapnic respiratory failure by comparing with nasal continuous positive airway pressure

Eligibility criteria:
inclusion criteria: * hypoxemic and no hypercapnic acute respiratory failure : * severe dyspnea at rest with a respiratory rate \>25 breaths/min * pao2/fio2 \<300 * paco2 \<45 mmhg, exclusion criteria: * age \<18 years * nppv contraindications * past history of respiratory chronic disease (copd, cystic fibrosis...) * cardiac pulmonary edema * pre-defined intubation * other than respiratory organ failure : systolic pressure \<90 mmhg,current treatment with epinephrine or norepinephrine, decreased level of consciousness ( glasgow score ≤ 12) * profound aplasia (white cells count \<1000/mm 3)
efficacy and immunomodulator impact of herbal combination on covid-19 patients recovery

Conditions: COVID 19

Summary: this study aims to evaluate the efficacy and safety of herbamuno+, a combination of several herbal ingredients, as an adjunct therapy for moderate covid-19 patients at wisma atlet. the study involves 66 patients who were divided into two groups: one receiving herbamuno+ and the other a placebo, both for 14 days. researchers monitored clinical improvements, chest x-rays, and blood tests to assess inflammation and immune response. the goal is to determine whether herbamuno+ can be safely and effectively added to standard covid-19 treatment.


Eligibility criteria:
inclusion criteria: * the rct included patients who met the following criteria: \&amp;gt;18 years old, had recently tested positive for covid-19 through rt-pcr within the past five days, and were categorized as moderate cases. the main clinical symptoms required for inclusion were acute fever (greater than 38 °c) and cough, or more than three of the following acute symptoms or signs: fever, cough, fatigue, headache, muscle pain, sore throat, nasal congestion, runny nose, shortness of breath, anorexia, nausea, vomiting, diarrhea, anosmia, or ageusia. the moderate case criteria are based on who criteria including the radiology imaging that indicating pneumonia (new infiltrates to consolidation) and clinical signs of pneumonia (fever, cough, shortness of breath, and respiratory frequency between 20 to 30 times per minute). exclusion criteria: * patients were excluded if they had any of the following conditions: an oxygen saturation of less than 93%, participating in other clinical trials, pregnant or lactating, receiving other immunomodulatory drugs, had a history of allergies to the test product, or the history of tuberculosis, hiv/aids, psychosis, or autoimmune disorders. subjects may also be dropped from the clinical trial if they withdraw, fail to comply with the protocol (including using less than 80% of the test product), disappear, or no longer meet the inclusion criteria. adverse events, worsening conditions, or new diagnoses during the trial also warrant exclusion.
surfactant for neonatal respiratory distress syndrome(nrds) and neonatal acute respiratory distress syndrome(nards)

Conditions: Respiratory Distress Syndrome; Preterm Birth; Acute Respiratory Distress Syndrome; Surfactant Dysfunction

Summary: in preterm infants with neonatal respiratory distress syndrome (nrds), exogenous pulmonary surfactant(ps) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. nowadays, ps is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(bpd) and/or death are inconsistent. the result indicates that not all preterm infants with respiratory distress can be beneficial from ps. in 2017, the international neonatal ards (nards) collaborative group provides the first consensus definition for nards. and whether or not ps being beneficial for preterm infants with nards remains unknown.

to date, ps is not recommended to adult and pediatric ards. meantime, systematic review indicates that ps does not demonstrate statistically significant beneficial effects on reducing the mortality and the rate of bpd in term and late preterm infants with meconium aspiration syndrome(mas). therefore, a reasonable speculation is that preterm infants with nards do not benefit from one dose of ps. and the speculation can explain why not all preterm infants with respiratory distress can be beneficial from ps. in the era of pre-nards, the preterm infants fulfilling the definition of nards may have been considered as nrds in the first three days after birth. according to the diagnostic criteria of nards, a key procedure for diagnosis of nards is to exclude the newborn infants with nrds. but no detailed procedures are available to differentiate nrds from nards.

Eligibility criteria:
inclusion criteria: eligibility requirements for neonates were as follows: * the gestational age is less than 37 weeks and admitted to neonatal intensive care unit(nicu) in 24 h after birth * the neonates will be diagnosed with nrds or nards * the neonates will be at least administrated one dose of surfactant exclusion criteria: one of the following criteria will be needed * major congenital anomalies * chromosomal abnormalities * upper respiratory tract abnormalities
peng vs. fic blocks in hip fractures in the ed

Conditions: Hip Fractures; Nerve Block; Analgesia

Summary: this study is a prospective, randomized clinical trial assessing the efficacy of physician-performed ultrasound-guided pericapsular nerve group (peng) block vs fascia iliaca compartment (fic) block for pain control in acute hip fracture.


Eligibility criteria:
inclusion criteria: * adult (\>= 18 years of age) * isolated proximal hip fracture (defined as intertrochanteric or more proximal) as identified by x-ray, computed tomography (ct) scan or magnetic resonance imaging (mri) scan * glasgow coma score (gcs) = 15 * subjective pain score of \>= 5 on a scale of 0 to 10 just prior to the nerve block placement exclusion criteria: * patients who are unable to give consent due to altered mental status or dementia * clinically intoxicated patients * patients who are unable to communicate their numeric level of pain * open fracture or penetrating hip trauma * signs of infection or laceration at injection site * patients with multi-system trauma * painful distracting injury (injury causing significant pain that distracts the patient from having reliable scoring of hip fracture pain, e.g. humerus fracture, dislocated joint) * requiring immediate surgical intervention (\< 1 hour) * deemed clinically unstable by treating physician * abnormal vital signs (pulse\>120bpm, systolic blood pressure \< 100 mm hg, pulse o2 \< 95%) * patients on long-acting systemic opioid analgesia * allergy to amide local anesthetics * vulnerable populations including pregnant patients, prisoners, children, elderly dementia patients. all precautions will be taken to avoid coercion, harm and exploitation of these vulnerable populations, thus they are to be excluded from this study. they will receive pain medications as deemed appropriate by their treating physician.
clinical evaluation of intravascular ultrasound diagnostic equipment and intravascular ultrasound diagnostic catheter

Conditions: Percutaneous Coronary Intervention (PCI); Coronary Artery Disease

Summary: the goal of this clinical trial is to evaluate the safety and effectiveness of intravascular ultrasound diagnostic instruments（referred to as pubmed ivus system） and disposable intravascular ultrasound diagnostic catheters（referred to as pubmed ivus catheters） in coronary intervention therapy. participants will: undergo ivus examinations from two different manufacturers（from pubmed and boston scientific）


Eligibility criteria:
inclusion criteria: * age: 18 years and older; * clinical evaluation shows that the coronary artery stent implantation and the intravascular ultrasound(ivus) guidance is required. * understand and willing to sign the informed consent form; exclusion criteria: * participants who are not suitable for percutaneous coronary stent implantation; * participants diagnosed with coronary artery spasm； * participants with a history of allergy to contrast agents; * participants in other clinical trials who have not yet reached the primary endpoint； * the investigator believe that the subjects are not suitable for inclusion in this study.
efficacy of a single preoperative administration of action observation therapy associated with motor imagery in patients undergoing total hip arthroplasty.

Conditions: Hip Osteoarthritis; Orthopedic Disorder

Summary: action observation therapy (aot) and motor imagery (mi) are two rehabilitation approaches based on mirror neuron system (mns). the mns refers to a series of neurons able to activate both when one observes an action being performed or when one physically performs the action themselves. previous studies reported that functional recovery is facilitated by asking patient observing videos with motor content (aot) and after imagining (mi) the gestures observed. these rehabilitative apporach have been used in particular to promote functional recovery in patients with neuromotor problems, in particular in patients with stroke. to date, few studies have investigated the effectiveness of this therapeutic approach in functional recovery after orthopedic surgery and none of these applied aot and mi in a single pre-operative session. the objective of the study is to verify whether a single administration consisting of two pre-operative sessions of aot associated with mi can lead to an improvement of functional recovery in hip arthroplasty patients.


Eligibility criteria:
inclusion criteria: * total hip arthroplasty (tha) monolateral, first implant * locomotor autonomy with or without aids before surgery * bmi (regular, overweight, grade i obesity) * no complications in surgery * orthopaedic prescription of tolerance load on the limb * autonomy with aids within the third post-operative day exclusion criteria: * previous total hip replacement on contralateral hip * dementia or other conditions affecting patient's collaboration * unresolved clinical complications in the first two post-operative days * neurological, musculoskeletal or other disorders able to impact on functional recovery * visual or auditory deficits * total or partial revisions of tha * patients assigned to different groups hospitalized in the same room

Keywords: action observation therapy motor imagery hip arthroplasty functional recovery